שולי רווח נקי ממכירות bioAffinity Technologies Inc. (BIAF)

סמל ולוגו של המותג bioAffinity Technologies, Inc. (BIAF)

Efficient express delivery of biomaterials ensures the diagnostic accuracy of bioAffinity Technologies. The sales margin trajectory based on GURU.Markets data, where the value -278.90 indicates the current magnitude, correlates with the CyPath Lung sputum analysis patents. Meanwhile, professional management in oncology diagnostics guarantees data transparency, although large-scale business development requires significant capital expenditures.

bioaffinitytech.com (BIAF) - שולי הרווח הנקי מ-28.04.2023 עד 19.11.2026

פילוחי נתונים אנליטיים מרוכזים עבור bioAffinity Technologies, Inc. (BIAF)

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח מסכם של החברה:bioAffinity Technologies, Inc. - BIAF
סחורת הדגל של bioaffinitytech.com

Amid market uncertainty, protecting capital from overvalued assets becomes the investor's priority. This indicator measures the portion of revenue converted into net profit after deducting all operating and tax expenses. By analyzing the net profit margin, one can determine the real efficiency of cost management. For bioAffinity Technologies (BIAF), this parameter reflects the cost of implementing innovations in cancer diagnostics. High-level biological expertise and grant support should convert into growth for this metric.